Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism

• Main Authors: Bin Li (Author), Qi Xiao (Author), Hongmei Zhao (Author), Jianuo Zhang (Author), Chunyan Yang (Author), Yucen Zou (Author), Bengang Zhang (Author), Jiushi Liu (Author), Haitao Sun (Author), Haitao Liu (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis, is a common metabolic liver disease worldwide. Currently, satisfactory drugs for NAFLD treatment remain lacking. Obesity and diabetes are the leading causes of NAFLD, and compounds with anti-obesity and anti-diabetic acti...